

U.S. PATENT DOCUMENTS						
Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)		
	Number	Kind Code (if known)				
FOREIGN PATENT DOCUMENTS						
Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no
SPC	EP 707071	A1	EUROPE	26.01.2000	✓	
NON-PATENT LITERATURE DOCUMENTS						
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
SPC	TOLLEFSON et al., "The Adenovirus Death Protein (E3-11.6K) is Required at Very Late Stages of Infection for Efficient Cell Lysis and Release of Adenovirus from Infected Cells", J. Virol., 1996, Vol. 70, p. 2296-2306, American Soc for Microb					
	SIGNAS et al., "An Adenovirus Glycoprotein Binds Heavy Chains of Class I Transplantation Antigen from Man and Mouse", Nature, Vol. 1982, 299, p. 175-178, Macmillian Journals Ltd.					
	BURGERT et al., "An Adenovirus Type 2 Glycoprotein Blocks Cell Surface Expression of Human Histocompatibility Class I Antigens", Cell, 1985 Vol. 41, p. 987-997, MIT					
	ANDERSSON et al., "Reduced Alloreognition of Adenovirus-2 Infected Cells", J. Immunol., 1987, Vol. 138, p. 3906-3966, The American Association of Immunologists					
	BROWNING AND RIBOLINI, "Studies of the Differing Effects of Tumor Necrosis Factor and Lymphotoxin on the Growth of Several Human Tumor Lines", J. Immunol., 1989, Vol. 143, p. 1859-1967, The American Association of Immunologists					
	MESTAN et al., "Antiviral Effects of Recombinant Tumour Necrosis Factor <i>In Vitro</i> ", Nature, 1986, Vol. 323, p. 816-819					
	YANG et al., "Cellular Immunity to Viral Antigens Limits E1-deleted Adenoviruses for Gene Therapy", Proc. Natl. Acad. Sci. USA, 1994, Vol. 91, p. 4407-4411, Medical Sciences					
	ZSENGELLER et al., Human Gene Therapy, 1995, Vol. 6, p. 457-467, Mary Ann Liebert, Inc. Publishers					
	YANG et al, "Cellular and Humoral Immune Responses to Viral Antigens Create Barriers to Lung-Directed Gene Therapy with Recombinant Adenoviruses", J. Virology, 1995, Vol. 69, p. 2004-2015, American Society for Microbiology					
	LAN et al., "Insertion of the Adenoviral E3 Region into a Recombinant Viral Vector Prevents Antiviral Humoral and Cellular Immune Responses and Permits Long-Term Gene Expression", Proc. Natl. Acad. Sci. USA, 1997, Vol. 94, p. 2587-2592, Medical Sciences					
✓	WOLD et al., "E3 Transcription Unit of Adenovirus", Current Topics in Microbiology and Immunology, 1995, Vol. 199, p.237-274, St. Louis University School of Medicine, Dept. of Molecular and Immunology					
Examiner Signature	Stacy B. Chen			Date Considered	October 7, 2004	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

ATTORNEY'S DKT NO.
032751-094

APPLICATION NO.

New 10/670,397

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Ronald ROOKEFILING DATE
September 26, 2003

GROUP

UNASSIGNED 1648

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		
SBC	6,100,086		Kaplan et al.	08-08-2000
SBC	5,851,806		Kovesdi et al.	12-22-1998

FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no
SBC	WO 99/02658	A1	PCT	01-21-1999	X	
	EP 0974668	A1	European Patent Office	01-26-2000	X	
	WO 96/12030	A1	PCT Abstract only	04-25-1996		X
	EP 0707071	A1	European Patent Office	04-17-1996	X	

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
SBC	HARROD, K.S. et al., "Adenoviral E3-14.7K Protein in LPS-induced Lung Inflammation", American Journal of Physiology, April 2000, Volume 278, No. 4, Part 1, pp. L631-L639.		
	KRAJCSI, P. et al., "The Adenovirus E3-14.7K Protein and the E3-10.4K/14.5K Complex of Proteins, Which Independently Inhibit Tumor Necrosis Factor (TNF)-induced Apoptosis, Also Independently Inhibit TNF-induced Release of Arachidonic Acid.", Journal of Virology, 1996, Volume 70, No. 8, pp. 4904-4913.		
	GANTZER, M. et al., "Constitutive Expression of the Adenovirus E3-14.7K Protein Does Not Prolong Adenovirus Vector DNA Persistence but Protects Mice Against Lipopolysaccharide-Induced Acute Hepatitis.", Human Gene Therapy, May 2002, Volume 13, No. 8, pp. 921-933.		
	International Search Report, June 7, 2002, for EPO Application No. 01120916.		
Examiner Signature	Stacy B. Chen	Date Considered	October 7, 2004

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.